Bluestein R H & Co. lessened its position in Allergan PLC. (NYSE:AGN) by 25.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,000 shares of the company’s stock after selling 1,000 shares during the period. Bluestein R H & Co.’s holdings in Allergan PLC. were worth $729,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Pathstone Family Office LLC increased its holdings in shares of Allergan PLC. by 3,327.3% in the 2nd quarter. Pathstone Family Office LLC now owns 377 shares of the company’s stock worth $2,035,000 after acquiring an additional 366 shares during the period. Howard Hughes Medical Institute acquired a new stake in shares of Allergan PLC. in the 2nd quarter worth about $103,000. Jacobi Capital Management LLC increased its holdings in shares of Allergan PLC. by 4.9% in the 1st quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after acquiring an additional 22 shares during the period. JNBA Financial Advisors increased its holdings in shares of Allergan PLC. by 2.5% in the 1st quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after acquiring an additional 12 shares during the period. Finally, Pacific Center for Financial Services increased its holdings in shares of Allergan PLC. by 805.1% in the 1st quarter. Pacific Center for Financial Services now owns 534 shares of the company’s stock worth $128,000 after acquiring an additional 475 shares during the period. 82.03% of the stock is currently owned by institutional investors and hedge funds.

Several research firms have commented on AGN. Wells Fargo & Company reissued a “buy” rating on shares of Allergan PLC. in a research note on Monday. Barclays PLC reissued an “equal weight” rating on shares of Allergan PLC. in a research note on Monday. UBS AG reissued a “buy” rating and set a $275.00 target price on shares of Allergan PLC. in a research note on Tuesday, September 26th. Credit Suisse Group reissued an “outperform” rating and set a $266.00 target price (down previously from $286.00) on shares of Allergan PLC. in a research note on Tuesday, September 26th. Finally, Mizuho reissued a “buy” rating and set a $267.00 target price on shares of Allergan PLC. in a research note on Monday, September 25th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $271.84.

TRADEMARK VIOLATION NOTICE: This piece was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/05/bluestein-r-h-co-has-729000-position-in-allergan-plc-agn.html.

Shares of Allergan PLC. (NYSE:AGN) opened at 208.39 on Thursday. The firm has a market cap of $69.67 billion, a P/E ratio of 6.35 and a beta of 1.15. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80. The firm’s 50-day moving average is $219.55 and its 200-day moving average is $233.54.

Allergan PLC. (NYSE:AGN) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping the consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion for the quarter, compared to analysts’ expectations of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The company’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same quarter last year, the business earned $3.35 EPS. On average, analysts anticipate that Allergan PLC. will post $16.22 EPS for the current fiscal year.

Allergan PLC. declared that its Board of Directors has approved a share buyback program on Monday, September 25th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 2.8% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board believes its shares are undervalued.

The business also recently declared a quarterly dividend, which was paid on Friday, September 15th. Investors of record on Friday, August 18th were given a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.34%. The ex-dividend date was Wednesday, August 16th. Allergan PLC.’s payout ratio is currently 9.95%.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.